Meeting Banner
Abstract #3593

1H MRS Reveals GABA and Glutamatergic Compound Elevations in Subjects at Ultra-High Risk for Schizophrenia

Camilo de la Fuente-Sandoval1, Pablo L. Ortiz2, Xiangling Mao3, Patricia Alavarado-Alanis4, Oscar Rodrguez-Mayoral5, Francisco Reyes-Madrigal4, Ariel Graff-Guerrero6, Rodolfo Solis-Vivanco7, Rafael Favila8, Dikoma C. Shungu3

1Neuropsychiatry & Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologa y Neurociruga (INNN), Mexico City, Distrito Federal, Mexico; 2Education, INNN, Mexico City, Distrito Federal, Mexico; 3Radiology, Weill Cornell Medical College, New York, NY, United States; 4Laboratory of Experimental Psychiatry, INNN, Mexico City, Distrito Federal, Mexico; 5Early Psychosis Intervention, Hospital Fray Bernardino Alvarez, Mexico City, Distrito Federal, Mexico; 6Multimodal Neuroimaging Schizophrenia Group, Centre for Addiction and Mental Health, Toronto, ON, Canada; 7Laboratory of Neuropsychology, INNN, Mexico City, Distrito Federal, Mexico; 8MR Advanced Applications, GE Healthcare, Mexico City, Distrito Federal, Mexico

In the present study, 1H MRS was used to investigate potential dysregulations of GABA and glutamatergic compounds in subjects at ultra-high risk (UHR) for schizophrenia compared to healthy controls, and found higher levels of both neurotransmitters in the striatum and medial prefrontal cortex of the UHR group.

Abstract PDF Presentation Video

Keywords

abuse acid addiction adulthood advanced affected agitation agreement amino among apparent appearance arch array assessed axis beyond blown brain cause challenging channel cited city clinical clinically collectively comprised concomitant considered context contradiction controls cortex currently debilitating dependence derived detection diagnosed disability discrepancy disorder duration early edited education elevated elevations evaluate excitations excitatory excluded excluding experimental exposed expressed federal females field finding findings fray full general glutamate great health healthy history identify illness impede in vivo informed intervention interview investigate investigations involvement laboratory lesions lewis literature making matched medial medical medication meeting mental neurological neurotransmitter neurotransmitters noninvasive normalize novel offer onset opportunity outcome patients peak permitted persist population postmortem potential prior progression psychiatry psychosis psychotic psychotropic radiology rationale recorded reliable remain replicate reported risk schizophrenia significantly simultaneously since sips sorting source spectra spectrum stages structured studied studies subjects substance substantial suggesting summary syndrome syndromes system systems transmitters treatment twenty ultra volunteer water worldwide young